Abstract
The introduction of effective and potent treatments for human immunodeficiency virus (HIV) infection resulted in prolonged survival and better quality of life of HIV-infected patients. However, the longer survival and the anti-HIV medication side effects caused the emergence of new clinical issues, such as the increase in cardiovascular risk, favored by multiple factors, partly related to HIV infection itself, partly to the anti-HIV molecules. HIV infection itself may affect cardiovascular risk through chronic inflammation induced by uncontrolled viral replication, whereas long-term antiretroviral therapy may increase the cardiovascular risk through several mechanisms. Thus, due to the multiple and conflicting causes of cardiovascular disorders in HIV-infected patients, clinicians should take into consideration all modifiable risk factors, in order to implement an effective prevention of this clinical issue.
Keywords: HIV infection, AIDS, atherosclerosis, cardiovascular risk, antiretroviral therapy, lipids, endothelium, human immunodeficiency virus (HIV), anti-HIVmedication, chronic inflammation, uncontrolled viral replication, efficacy of the combination antiretroviral treatment (cART), dyslipidemia, insulinresistance and endothelial damage
Current Pharmaceutical Biotechnology
Title: HIV and Accelerated Atheroprogression: Role of Antiretroviral Therapy
Volume: 13 Issue: 1
Author(s): Antonio Di Biagio, Valerio Del Bono, Raffaella Rosso and Claudio Viscoli
Affiliation:
Keywords: HIV infection, AIDS, atherosclerosis, cardiovascular risk, antiretroviral therapy, lipids, endothelium, human immunodeficiency virus (HIV), anti-HIVmedication, chronic inflammation, uncontrolled viral replication, efficacy of the combination antiretroviral treatment (cART), dyslipidemia, insulinresistance and endothelial damage
Abstract: The introduction of effective and potent treatments for human immunodeficiency virus (HIV) infection resulted in prolonged survival and better quality of life of HIV-infected patients. However, the longer survival and the anti-HIV medication side effects caused the emergence of new clinical issues, such as the increase in cardiovascular risk, favored by multiple factors, partly related to HIV infection itself, partly to the anti-HIV molecules. HIV infection itself may affect cardiovascular risk through chronic inflammation induced by uncontrolled viral replication, whereas long-term antiretroviral therapy may increase the cardiovascular risk through several mechanisms. Thus, due to the multiple and conflicting causes of cardiovascular disorders in HIV-infected patients, clinicians should take into consideration all modifiable risk factors, in order to implement an effective prevention of this clinical issue.
Export Options
About this article
Cite this article as:
Di Biagio Antonio, Del Bono Valerio, Rosso Raffaella and Viscoli Claudio, HIV and Accelerated Atheroprogression: Role of Antiretroviral Therapy, Current Pharmaceutical Biotechnology 2012; 13 (1) . https://dx.doi.org/10.2174/138920112798868520
DOI https://dx.doi.org/10.2174/138920112798868520 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Bioactive Polyphenols from Healthy Diets and Forest Biomass
Current Nutrition & Food Science Novel Rational Drug Design Strategies with Potential to Revolutionize Malaria Chemotherapy
Current Medicinal Chemistry Physico-chemical and Biological Evaluation of Flavonols: Fisetin, Quercetin and Kaempferol Alone and Incorporated in beta Cyclodextrins
Anti-Cancer Agents in Medicinal Chemistry Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review
Current Cardiology Reviews Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Antigenicity Prediction in Melittin: Possibilities of in Drug Development from Apis dorsata
Current Proteomics Implantable Microfluidic Device: An Epoch of Technology
Current Pharmaceutical Design Hyperthermia: From Diagnostic and Treatments to New Discoveries
Recent Patents on Biotechnology Intestinal Barrier Dysfunction in Human Pathology and Aging
Current Pharmaceutical Design Protein Kinase A (PKA) - A Potential Target for Therapeutic Intervention of Dysfunctional Immune Cells
Current Drug Targets Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics
Current Cardiology Reviews MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Liver Injury Associated with Antidepressants
Current Drug Safety